PCI Biotech Holding ASA: PCI Biotech interim first quarter 2022 results

Oslo (Norway), 11 May 2022 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2022 results. Please find enclosed the report and presentation. Highlights fimaVacc*The

Related Keywords

Germany ,Norway ,United States ,Denmark ,Munich ,Bayern ,United Kingdom ,Sweden ,Oslo ,South Korea ,Norwegian ,South Korean ,Ronny Skuggedal ,Ludovic Robin ,Ernst Wagner ,Hans Peter ,Scientific Advisory Committee ,Biotech Holding ,Per Walday ,Quarterly Report ,Norwegian Securities Trading ,Biotech ,Molding ,Interim ,First ,Quarter ,022 ,Results ,